F star Therapeutics Inc (FSTX) Noticias

https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d9a.htm
And last one I hope. Lol....

https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d9a.htm
Here is more information on this.

https://www.sec.gov/Archives/edgar/data/1566373/000119312522309500/d439272d8k.htm
Looks like good news to me

invoX Pharma to Acquire F-Star Therapeutics (FSTX) for $7.12 Per Share
https://www.streetinsider.com/Corporate+News/invoX+Pharma+to+Acquire+F-Star+Therapeutics+%28FSTX%29+for+%247.12+Per+Share/20245945.html

someone has been hitting the sell button for 5 days straight, this is getting ridiculous that it can't move on major news like that, but these other stocks move 2 to 3 hundred percent on nothing

FJB!!!

Let's go Brandon! FJB

Kinda crazy this hasn’t taken off with this mega license deal

Big news

F-star Therapeutics Reports License Deal With J&J's Janssen To Develop, Commercialize Multiple Next Gen Bispecific Antibody Therapeutics; Co. To Receive Upfront Fees Of $17.5M, Near-Term Fees, Milestones Up To $1.35B
8:04 am ET October 20, 2021 (Benzinga) Print
F-star Therapeutics, Ltd. (NASDAQ:FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation.

Under the terms of the agreement, F-star will grant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab™ and mAb2™ platforms. Janssen will be responsible for all research, development, and commercialization activities under the agreement.

Neil Brewis, Ph.D., Chief Scientific Officer of F-star said, “We are pleased to collaborate with Janssen and leverage the science of F-star’s proprietary tetravalent bispecific technology. Beyond our proprietary pipeline, we believe there is broad potential for our mAb2 platform to produce multiple next-generation bispecific antibody therapeutics.”

Under the terms of the agreement F-star is entitled to receive upfront fees of $17.5 million, near-term fees and potential further milestones of up to $1.35 billion. F-star is also eligible to receive potential tiered mid-single digit royalties on annual net sales.

Form SC 13G F-star Therapeutics, Inc.

https://sec.report/Document/0001104659-21-010211/

Jasper Bos of Merck had been observer to BOD.

F-star pipeline includes partnered programs with Merck and Denali

Therapeutics.

https://www.f-star.com/pipeline/proprietary-pipeline/